The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-20105", a Category 1 therapeutic biological product self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Changzhou Hansoh Pharmaceutical Company Limited ("Ch Chang Zhou Heng Bang Yao Ye You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumors. The specific indication will be determined after the completion of clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.1 HKD | +2.49% | -0.44% | +14.85% |
04-30 | Hansoh Pharmaceutical’s 2023 Profit Up 27% | MT |
04-29 | Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.85% | 13.72B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 3692 Stock
- News Hansoh Pharmaceutical Group Company Limited
- Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"